The point aiui is mostly arguing that the FDA errs too much on the side of caution in this area, and the trade-off would have been worth it to approve earlier. Not insinuating that like, there was some corruption (or laziness or something) that delayed it.
The point aiui is mostly arguing that the FDA errs too much on the side of caution in this area, and the trade-off would have been worth it to approve earlier. Not insinuating that like, there was some corruption (or laziness or something) that delayed it.